Results 161 to 170 of about 1,581,690 (305)

Checkpoint inhibitors, obinutuzumab plus PET‐adapted ultra‐low dose nodal radiotherapy yield high efficacy in treatment‐naïve follicular lymphoma: Results from the phase II ‘FLUORO’ study

British Journal of Haematology, EarlyView.
Summary Follicular lymphoma (FL) first‐line chemoimmunotherapy yields high efficacy but serious toxicity in 65% of patients. In high tumour burden treatment‐naïve FL, we aimed to exploit known immunostimulatory and cytotoxic properties of combination checkpoint inhibition (atezolizumab) and obinutuzumab (6 cycles) with positron emission tomography (PET)
Arina Martynchyk, Geoffrey Chong, Richard Khor, Denise Lee, Sze Ting Lee, Andrew M. Scott, Anneke C. Grobler, Belinda A. Campbell, Thanuja Thachil, Kate Manos, Genevieve Douglas, Alexandra Romano, Jodie B. Palmer, Melinda Burgess, Colm Keane, Eliza A. Hawkes   +15 more
wiley   +1 more source

Deciphering the full spectrum of Castleman diseases based on a cohort of 700 patients in a western country

British Journal of Haematology, EarlyView.
The spectrum of Castleman diseases has expanded over the past three decades. The phenotype of the diseases varies not only among the three major types but also according to the patient ancestry. Summary Under the Castleman disease (CD) eponym, three distinct diseases sharing common pathological features have been described over time.
Eric Oksenhendler, Marion Malphettes, Véronique Meignin, David Boutboul, Lionel Galicier   +4 more
wiley   +1 more source

Algorithms in Allergy: General Allergen Molecule‐Based Algorithm for Allergen‐Specific Immunotherapy

Allergy, EarlyView.
Huey‐Jy Huang, Daria Trifonova, Pia Gattinger, Stephanie Dramburg, Marek Jutel, Paolo Maria Matricardi, Rudolf Valenta   +6 more
wiley   +1 more source

Docetaxel‐Induced Immune Activation Shows Antitumor Synergy With the Tumor‐Targeted CD40 Agonist KK2269

Cancer Science, EarlyView.
CD40 agonists have demonstrated proof‐of‐concept for converting an immunologically cold tumor into a hot tumor in preclinical studies; however, clinically, they have shown limited antitumor efficacy as monotherapy. We tested a tumor‐targeted CD40 agonist, KK2269 (a bispecific antibody that binds to CD40 and EpCAM), in combination with various ...
Yuta Tezuka, Kyoko Kawasaki, Yoshiki Sumitomo, Masato Saito, Akari Yao, Munetoshi Ando   +5 more
wiley   +1 more source

Patient‐Derived IgG Epitope Mapping of Bet v 1 Reveals Hypoallergenic Peptide Candidates for Safe and Next‐Generation Allergen Immunotherapy

Clinical &Experimental Allergy, EarlyView.
Mapping IgG epitopes of the major birch allergen Bet v 1 identified patient‐derived, hypoallergenic peptides that did not trigger degranulation. These findings support a novel, safer approach for peptide‐based allergen immunotherapy that leverages naturally induced IgG specificities from allergic individuals. ABSTRACT Background Allergen immunotherapy (
Lara Šošić, Marta Paolucci, Alessandro Streuli, David A. Melillo, Tianchi Jiang, Raffaela Campana, Claudia C. V. Lang, Thomas M. Kündig, Christian Steuer, Klaus Eyer, Pål Johansen   +10 more
wiley   +1 more source

LABRAD : Vol 41, Issue 2 - July 2015 [PDF]

, 2015
An Overview of Immunoglobulin G4-Related Disease Plasma Neutrophil Gelatinase Associated Lipocalin (NGAL) a Marker of Acute Kidney Injury Celiac Disease: Biomarkers for Diagnosis and Monitoring Pathophysiology of Paroxysmal Nocturnal Haemoglobinuria and ...
Aga Khan Universiity Hospital, Karachi
core   +1 more source

Sustained Clinical Improvement in Birch Pollen Allergy After Two Pre‐Seasonal Short Courses of Allergen‐Specific Immunotherapy: A Long‐Term Open‐Label Extension Study

Clinical &Experimental Allergy, EarlyView.
3 years follow‐up study to a DBPC dose‐finding trial investigating subcutaneous immunotherapy with T502 in birch‐pollen induced allergic rhinoconjunctivitis. 154 birch‐pollen allergic adults received short‐course treatment of 10,000 mTU/mL of T502 for 2 years and were observed during the next season without treatment.
Ralph Mösges, Friederike Hüffmeier, Ludger Klimek, Oliver Pfaar, Christian Neuhof, Anna Rybachuk, Cengizhan Acikel, Hacer Sahin, Silke Allekotte, Sandra del Pozo, José Luis Subiza, Miguel Casanovas, Mandy Cuevas, Laura Day, Lea Radtke, Esther Raskopf   +15 more
wiley   +1 more source

Cutaneous Crystal‐Storing Histiocytosis With Marginal Zone Lymphoma. A Case Report With A Striking Clinical Presentation

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Cutaneous crystal‐storing histiocytosis (CSH) is an extremely rare histopathologic finding of histiocytes accumulating crystals of immunoglobulin or paraproteins, often associated with lymphoplasmacytic malignancies. It commonly presents in a wide age range of both female and male adults with a history of a lymphoproliferative disorder ...
Ashton Arlen, Brad S. Graham, Gregory A. Hosler, Marsha C. Kinney   +3 more
wiley   +1 more source

A Rare Case of Cutaneous Crystal‐Storing Histiocytosis With Kappa Light Chain Restriction and Unusual BCL6 Expression

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Crystal‐storing histiocytosis (CSH) is a rare histopathologic phenomenon characterized by the accumulation of crystalline material within histiocytes, most often associated with lymphoplasmacytic or plasma cell neoplasms. Cutaneous involvement is uncommon and may present diagnostic challenges.
Liangli Wang, Jonathan L. Curry, Julia Dai, Daniel H. Wang, Paolo Strati, Melody R. Becnel, Leomar Y. Ballester, Carlos A. Torres‐Cabala, Phyu P. Aung   +8 more
wiley   +1 more source

Chronic ulcerative oesophagitis rich in IgG4‐positive plasma cells – a distinct clinicopathological entity

Histopathology, EarlyView.
We report a series of 12 patients (mean age 63 years) with chronic oesophageal ulceration showing morphological features of IgG4‐related inflammatory disease. Most patients underwent several rounds of endoscopy until this association was recognized. The majority of patients went into clinical and histological remission following corticosteroid therapy.
Hanna Henzinger, Ian Brown, Anthony J Gill, Tomas Slavik, Giuseppe Zamboni, Cord Langner   +5 more
wiley   +1 more source